CGEM vs CLDI

Cullinan Therapeutics, Inc. vs Calidi Biotherapeutics, Inc. — Valuation Comparison 2026

CGEM

Biological Products, (No Diagnostic Substances)
Cullinan Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$16.44
Last close
Models
7/13
Active
VS

CLDI

Biological Products, (No Diagnostic Substances)
Calidi Biotherapeutics, Inc.
Quality
4.2
out of 10
Value Trap
39
LOW
Price
$0.18
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType CGEM Fair ValueCGEM Upside CLDI Fair ValueCLDI Upside
Bayesian DCF Intrinsic $4.42 -73.1% $0.17 -8.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.71 -89.6% $1.04 +462.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CGEM vs CLDI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CGEM vs CLDI — Which Stock Is More Undervalued?

CGEM scores higher with a 4.4/10 quality rating vs CLDI's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cullinan Therapeutics, Inc. (CGEM) and Calidi Biotherapeutics, Inc. (CLDI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CGEM currently trades at $16.44 with a QOC of 4.4/10, while CLDI trades at $0.18 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).